XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Contingent consideration 1 (Tables)
 6 Months Ended
Dec. 31, 2023
Text block [abstract]  
Summary of liabilities - contingent consideration
    
Consolidated
  
    
December
2023
     
June 2023
  
    
$
     
$
  
Contingent consideration — Paxalisib
      750,499        653,692  
Contingent consideration — EVT801
      4,809,490        5,467,091  
  
 
 
     
 
 
  
     5,559,989        6,120,783  
  
 
 
     
 
 
  
Summary of reconciliation of contingent consideration
    
Consolidated
  
    
December
2023
     
June 2023
  
    
$
     
$
  
Reconciliation of the balance at the beginning and end of the reporting period is set out below:
      
Contingent consideration at start of period (current and non-current)
      6,870,783        8,967,785  
Interest
      220,484        593,462  
Foreign currency (gain)/loss
      (139,043 )       697,233  
Loss/(Gain) on revaluation of contingent consideration
      166,696        (3,387,697 ) 
  
 
 
     
 
 
  
     7,118,920        6,870,783